A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

• Status: Completed
• Trial end date: 2007-12-01

Summary

The purpose of this study is to evaluate the antiretroviral efficacy, safety, and tolerability of fos-amprenavir boosted with either of two doses of ritonavir (RTV) when administered in combination with ABC/3TC (abacavir/lamivudine, Epzicom®) FDC (fixed dose combination) in a once-daily regimen over 96 weeks in ART-naïve, HIV-infected adults

• Phase: Phase 4

Details

• Lead Sponsor: Duke University
• Collaborator: GlaxoSmithKline
• Treatments: Abacavir; Amprenavir; Calcium; Fosamprenavir; Lamivudine; Ritonavir